Cellbiotech has invited medical professionals and partners from Indonesia and Singapore to showcase its research and development (R&D) capabilities and production facilities. The company aims to strengthen its presence in the international market for K-probiotics through expanded collaboration with global healthcare providers.
On July 29, Cellbiotech announced that it hosted 64 key doctors and partners from Indonesia and Singapore at its headquarters in Gimpo, where they were introduced to the company's R&D capabilities and production facilities.
The event was designed to allow attendees to experience Cellbiotech's proprietary technology and production infrastructure firsthand. Participants toured the research and production facilities, assessing the company's R&D capabilities and quality control systems, while discussing collaboration strategies for expanding into local markets. A cultural exchange program based on Korean food was also conducted.
Cellbiotech has been achieving success in international markets, leveraging global partnerships and technological competitiveness. Over the past 13 years, the company has exported a cumulative total of 538.5 billion won in probiotics, with 268.8 billion won, or nearly 50%, coming from exports, maintaining its position as the top exporter of probiotics in South Korea for 13 consecutive years. Currently, K-probiotics are exported to 55 countries, including Denmark, Turkey, Russia, and Mexico.
Indonesia and Singapore are key export markets where Cellbiotech has established a strong foundation. The company entered the Indonesian market in 2001, pioneering the market with its proprietary CBT probiotics and currently holds the number one market share. In 2015, it launched the 'DUOLAC' brand in Singapore, achieving the top position in the ethical pharmaceutical (ETC) market.
Indonesia presents a challenging market due to strict regulations, including halal certification. The Indonesian Food and Drug Authority (BPOM) requires registration of the genus and species of probiotics, as well as the unique strain numbers from manufacturers, and scientific evidence must be provided for health functional food approval.
As of now, 103 probiotic strains are registered with the Indonesian Food and Drug Authority, six of which are Cellbiotech's CBT probiotics. The core strains used in DUOLAC products include CBT-LR5, CBT-LA1, CBT-LP3, CBT-BG7, CBT-BF3, and CBT-ST3.
The foundation of Cellbiotech's competitiveness lies in its 'Dual Coating' technology. The company offers products designed to ensure that probiotics survive and reach the intestines, based on its globally patented dual coating technology.
Cellbiotech explained that in temperature stability tests conducted at 40 degrees Celsius for two weeks, dual-coated probiotics demonstrated survival rates thousands of times higher than non-coated probiotics. This dual coating technology ensures stability across a wide range of temperatures, from minus 70 degrees to plus 40 degrees, supporting its export competitiveness in 55 countries.
A Cellbiotech representative stated, "In many countries, including Indonesia and Singapore, probiotic products are distributed primarily through doctors and pharmacists, making trust with healthcare professionals a crucial factor in market competitiveness. We aim to solidify our collaboration with local medical professionals and partners through this invitation event and accelerate our efforts to penetrate international markets by expanding exchanges with global healthcare providers."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.